Home / News / India /  Sputnik Light may get nod soon: RDIF
Listen to this article

NEW DELHI : The Russian Direct Investment Fund (RDIF) that financially supports Russia’s one-shot covid-19 vaccine Sputnik Light, on Monday, said the vaccine is expected to be authorized in India soon as a standalone jab and a universal booster. 

RDIF said that it is actively cooperating with India’s regulatory authorities on registration of Sputnik Light.

“A major partner of RDIF, Dr. Reddy’s Laboratories, has conducted additional clinical trials of Sputnik Light in India. Positive data from these trials has also been presented to India’s regulator," RDIF said in a statement.

RDIF has also provided India’s regulator with documents for registration of Sputnik M–the vaccine for adolescents aged 12-17. Subject to positive decision of India’s authorities, RDIF said, Sputnik M could become the first foreign registered vaccine for adolescents in the country and make an important contribution in protecting the younger population. 

“Russia and India have joined forces since the beginning of the pandemic, with this strategic partnership including production of Sputnik V and Sputnik Light vaccines," Kirill Dmitriev, chief executive officer of RDIF said.

“A number of agreements with partners in India have helped RDIF to significantly increase our production capabilities. We are ready to offer the Sputnik Light vaccine and the Sputnik M vaccine for adolescents to support strong herd immunity in India and continue saving millions of lives," Dmitriev said. 

The Sputnik V vaccine is already used in India following an emergency use authorization in April 2021. Sputnik V became the first foreign-made vaccine used in India. 

Sputnik V has been authorized in 71 countries with total population of over 4 billion people. To facilitate the necessary production capacities, RDIF has reached agreements with leading Indian pharmaceutical companies, including Serum Institute of India (the world’s largest vaccine producer), Gland Pharma, Hetero Biopharma, Panacea Biotec, Stelis Biopharma, Virchow Biotech and Morepen. Today, India is the leading production hub for Sputnik V and Sputnik Light vaccines. 

The latest findings by the Gamaleya Center based on data from 28,000 subjects in Moscow have demonstrated that one-shot Sputnik Light administered standalone has 70% efficacy against infection from the Delta variant of coronavirus during the first three months after vaccination. 

The vaccine is 75% effective among subjects under the age of 60. Efficacy of Sputnik Light as a booster against Delta variant for other vaccines will be close to the efficacy against the Delta variant of the Sputnik V vaccine: over 83% against infection and over 94% against hospitalization, the RDIF said in a statement. 

Sputnik Light has proven to be safe and highly effective by real-world vaccination data. In particular, the vaccine has demonstrated efficacy of between 78.6-83.7% among the elderly as confirmed by the ministry of health of  Argentina.

Subscribe to Mint Newsletters
* Enter a valid email
* Thank you for subscribing to our newsletter.

Never miss a story! Stay connected and informed with Mint. Download our App Now!!

Edit Profile
Get alerts on WhatsApp
My ReadsRedeem a Gift CardLogout